Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
09 May 2020

Dear Students

UPDATE ON DEVELOPMENTS AT THE UFS

I hope you are well, healthy, and safe. I also hope that you are engaging with your friends and lecturers regularly, and that you have settled into the online learning environment. As with communities around the world – including higher education institutions – Kovsies also feel the impact of the exceptional circumstances resulting from the global COVID-19 outbreak. So much has changed, and our lives are directly and indirectly affected. It is a true test of our resilience and ability to adapt to a changing environment.

I know that it has not always been easy for you – none of us were prepared for a global pandemic of this magnitude. But I also see this as an opportunity for us to develop our learning and teaching model and to find ways of further enhancing the university’s processes and systems.

The suspension of the academic programme and the national lockdown had a huge effect on our staff and students. We had to act fast to ensure the continuation of the 2020 academic programme. Our first priority was to develop low-tech online and distance approaches to learning and teaching. Consequently, we developed support for academic staff and students to navigate the new online learning environment. We also revised our academic calendar and rolled out a carefully planned emergency remote teaching and learning methodology.

It is encouraging to know that you began with online learning this week. Early indications are that the Transition and Orientation from 20 to 30 April 2020 worked well in preparing you for the online learning that started on 4 May 2020. It is also good to know that the #UFSLearnOn material helped you to get ready for the start of online academic activities. Be assured that your lecturers are working hard to deliver a quality teaching and learning experience in the current circumstances. Just as this is a new experience for you, it is also a new learning experience for your lecturers. You may still experience some challenges with your academics as we complete the first week of online learning. Please contact your lecturers and/or faculties so that we can find solutions for you. You can also visit the Digital Life Portal (under the Student Toolbox) on the KovsieLife website.

You have been away from your lecturers, friends, familiar surroundings, and campus facilities for a long time, and I know that you miss it. Unfortunately, the university is bound by Level 4 restrictions and it is not possible to allow any students back on our campuses until so directed by the national government. Only final-year MB ChB students are allowed to return to campus next week – as per the directive from the national government. The majority of staff are also working from home until otherwise indicated, and in accordance with national directives for the further easing of lockdown restrictions.

This is not a university decision but is prescribed in terms of national regulations. Be assured that the university has taken adequate measures to ensure the safety of all facilities, assets, and private belongings on the campuses. We will let you know as soon as we receive a directive that students may be allowed on campus – this will be done in a phased approach in order to contain the spread of COVID-19.

Your safety, health, and well-being remain our first priority. Look after yourself and your mental health – make use of the #WellnessWarriors campaign of our Department of Student Counselling and Development that is aimed at encouraging health and well-being among students.

Please remember to regularly check the official communication platforms to stay up to date with developments at the university. Avoid fake news, verify information, and only consult the official communication platforms. 

Obeying the lockdown restrictions is an act of kindness to yourself and to others; #StayAtHome and practise social distancing.

I wish you all the best with your studies and hope to see you on our campuses soon.


Best regards

Prof Francis Petersen
Rector and Vice-Chancellor


News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept